Genes and Geography Shape Severity of β-Thalassemia Intermedia

β-thalassemia intermedia has long frustrated clinicians because two patients carrying apparently similar β-globin mutations can end up on opposite ends of the transfusion spectrum. A systematic review published in Molecular Genetics & Genomic Medicine set out to explain that variability by mapping genotype–phenotype correlations across geographic regions, deliberately excluding HbE β-thalassemia to keep the analysis focused on classical genetic modifiers. The review, conducted and reported under PRISMA 2020 guidelines, searched PubMed from database inception to May 2026, screened 2166 records, assessed 137 full-text articles, and included 21 observational studies in a final qualitative synthesis.

The review’s central conclusion is that the clinical phenotype of β-thalassemia intermedia is not determined solely by the β-globin genotype. Instead, severity emerges from an interplay of genetic modifiers that regulate globin chain balance and erythropoiesis: the severity of β-globin mutations themselves, co-inheritance of α-thalassemia, α-globin gene triplication, and polymorphisms governing γ-globin expression. Co-inherited α-thalassemia reduces excess α-globin chain production and ameliorates severity, whereas α-globin gene triplication exacerbates α-chain excess and can convert an otherwise asymptomatic β-thalassemia heterozygote into clinically significant disease. HbF-modulating factors, including the XmnI site in the γ-globin promoter and trans-acting quantitative trait loci such as BCL11A and the HBS1L-MYB intergenic region, can substantially raise fetal haemoglobin levels and partially compensate for β-globin deficiency.

Because the relative contribution of these mechanisms varies across populations—likely shaped by historical migration, founder effects, genetic drift, and selective pressure from malaria—the authors grouped findings into four regions: Mediterranean, European, Middle Eastern, and Asian. In Mediterranean populations, β-thalassemia intermedia arose predominantly from homozygous or compound heterozygous states, accounting for roughly 82% to 100% of cases, and mild β-globin mutations were the principal modifying factor in most cohorts. Cypriot data illustrate the pattern: despite a high frequency of the severe IVS-I-110 (G>A) mutation, at about 74% to 80% of alleles, α-thalassemia co-inheritance appeared in roughly 52% of patients and was associated with phenotypic amelioration, with mean haemoglobin levels around 7.5 g/dL.

Sardinian cohorts tell a similar story. Although severe β0 mutations such as codon 39 predominated, all patients with thalassemia intermedia were non-transfusion-dependent, with mean haemoglobin levels of approximately 9.7 g/dL. That amelioration was strongly associated with co-inherited α-thalassemia, particularly the two-gene deletion, as well as the XmnI polymorphism, which enhances fetal haemoglobin production. Studies from Italy, Turkey, and Greece consistently attributed a substantial proportion of cases to at least one mild β-globin allele; in Italy, approximately 72% of patients did not require regular transfusions and diagnosis was often delayed beyond the age of 2 years. An earlier molecular characterization of 23 Italian patients found that inheritance of at least one mild β-thalassemia allele—β+-IVS-I-6, β−87, or β−101—was the most common mechanism underlying the intermedia phenotype, and it also identified three novel β-thalassemia mutations in patients with atypical single-allele genotypes.

The Eastern Mediterranean adds nuance to this framework. Israeli cohorts showed notable genetic heterogeneity, with a proportion of cases remaining unexplained despite detailed molecular analysis. Lebanese patients frequently carried the XmnI Gγ polymorphism alongside mild β-globin alleles, an association linked to increased HbF production and a predominantly non-transfusion-dependent phenotype. Palestinian cohorts, largely homozygous for IVS-I-6, showed greater variability in haemoglobin and HbF levels, with higher rates of transfusion dependence and splenectomy. These findings indicate that while mild β-globin mutations form the primary genetic basis in the region, HbF-related modifiers play a critical role in determining phenotypic severity and contribute to inter-population variability.

The European cohorts reveal a mechanistically distinct disease pathway in which α-globin gene dosage, rather than β-globin mutation severity, drives the phenotype. In a Spanish cohort of 73 patients, β-thalassemia intermedia arose from co-inheritance of an α-globin gene triplication with heterozygous β-thalassemia; 94.5% carried a single extra α-gene copy, and a smaller subset also carried a co-inherited δβ-thalassemia or Hb Lepore allele. Despite the shared triplication-driven mechanism, severity varied: 24.7% had a silent or mild phenotype, 56.2% a moderate phenotype, and 19.2% required regular transfusion. A French cohort of 45 patients showed that transfusion requirements tracked triplication dosage closely—64.4% of the heterozygous-triplication group needed no transfusion and 29% needed occasional transfusion, whereas all patients requiring regular transfusion carried the more severe homozygous triplication with six functional α-genes.

Middle Eastern cohorts present a different molecular profile, in which HbF induction, most commonly mediated by the XmnI polymorphism, acts as the primary modifier of phenotypic expression. Iranian data make this especially clear: approximately 55% of patients in one molecular study carried the XmnI polymorphism in association with severe β-globin mutations, producing mean HbF values around 56%. A cohort from South-East Iran showed an even higher prevalence of the polymorphism, near 62%, with a strong association with markedly increased HbF levels, often exceeding 50% and reaching up to 85% in homozygous individuals. Iraqi cohorts showed a similar but less pronounced pattern, with the XmnI polymorphism present in 22% of cases alongside mild β-globin alleles in 55%, associated with predominantly non-transfusion-dependent phenotypes and moderate haemoglobin levels averaging 8.3 g/dL.

Asian cohorts displayed the greatest molecular heterogeneity, with a higher prevalence of heterozygous states and a dominant role for α-globin gene modifications. In India, approximately 32% of β-thalassemia intermedia cases occurred in heterozygotes; among homozygous or compound heterozygous patients, α-thalassemia co-inheritance and XmnI polymorphism were key modifiers, whereas heterozygous cases were frequently associated with α-globin gene triplication. Southern China showed a more genotype-centric pattern, with roughly 42% of patients carrying at least one mild β-allele, relatively uncommon α-thalassemia co-inheritance, and a mutational spectrum dominated by recurrent variants such as CD41/42 and IVS-II-654. Sri Lanka demonstrated a distinct model in which approximately 66% of cases occurred in heterozygous individuals, with α-globin gene triplication present in 56%—among the highest frequencies reported globally—exacerbating globin chain imbalance and converting otherwise asymptomatic carriers into clinically significant disease.

The authors emphasize that these regional patterns should be interpreted as trends within the available literature rather than established population-level characteristics. Most included studies were conducted at single centers with relatively small sample sizes, limiting generalizability, and phenotype definitions were not uniform across studies, with inconsistent classification of transfusion dependence and disease severity. Molecular diagnostic techniques also differed according to study period and available technology. Several studies reported patients whose clinical phenotype could not be fully explained by known genetic modifiers, suggesting additional, yet unidentified regulatory factors contribute to disease variability. The proposed three-axis framework—β-globin mutation severity, α-globin gene dosage, and HbF-modulating factors—is explicitly hypothesis-generating rather than predictive or validated, and would require prospective validation before informing individualized management. The included studies did not directly evaluate treatment response, so potential therapeutic implications, such as differential effects of HbF-inducing agents according to molecular profile, remain hypothesis-generating and require validation in prospective clinical studies. Future research integrating genomic data with standardized clinical phenotyping across diverse populations, the authors conclude, will be critical to advancing precision medicine in β-thalassemia intermedia.

Subject of Research: Geographic genotype–phenotype correlations in non-HbE β-thalassemia intermedia

Article Title: Genotypic‐Phenotypic Correlations in Non‐HbE β‐Thalassemia Intermedia: A Geographic Systematic Review

Article References: Fernando, K., Perera, S., & Premawardhena, A. (2026). Genotypic‐Phenotypic Correlations in Non‐ HbE β‐Thalassemia Intermedia: A Geographic Systematic Review. Molecular Genetics & Genomic Medicine, 14(11), Article e70330. https://doi.org/10.1002/mgg3.70330

Image Credits: AI Generated

DOI: 10.1002/mgg3.70330

Keywords: β-thalassemia intermedia, genotype–phenotype correlation, systematic review, α-globin triplication, XmnI polymorphism, fetal haemoglobin, BCL11A, HBS1L-MYB, Mediterranean, Middle East, genetic modifiers, transfusion dependence